Hot Pursuit     15-Jun-24
Jubilant Pharmova unit to prepay $75 mln term loan
Jubilant Pharmova said that its subsidiary, Jubilant Pharma Holdings Inc., USA (JPHI) has issued a notice to its lenders to voluntary prepay $75 million term loan, equivalent to Rs 626 crore, by the next interest payment date i.e. 24th June 2024.
Jubilant Pharma Holdings Inc., USA (JPHI) is a wholly-owned subsidiary of Jubilant Pharma (JPL), which itself is a part of Jubilant Pharmova.

As on 31st March 2024, Jubilant Pharmova reported gross debt at Rs 3,414 crore and net debt at Rs 2,457 crore. on a consolidated basis.

Meanwhile, Jubilant Pharmova said that its subsidiary, Jubilant Draximage Inc., announced an investment of $50 million to expand its (Positron Emission Tomography) PET radiopharmacy network in strategic locations throughout the United States (US).

The US radiopharmaceutical industry is poised to grow from $5 billion in 2023 to $20 billion in 2030 due to the increasing demand of PET imaging and advance radiopharmaceutical therapies.

The company will add 6 PET radiopharmacies in US. It shall be operational by Financial Year 2027-28. This investment will expand the company’s PET radiopharmacy network to nine (9) sites and overall radiopharmacy network to fifty two (52) sites, solidly positioning Jubilant’s radiopharmacy network as the second largest in the US.

Harsher Singh, CEO, Jubilant Radiopharma business, said, “This investment shall help us meet increasing demand of novel PET products from our customers. With a much stronger PET radiopharmacy network, we also expect to secure long-term contracts with leading PET radiopharmaceutical manufacturers. We remain committed to improve patient lives through nuclear medicine.”

Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses.

The company has reported a net loss of Rs 58.60 crore in Q4 FY24 as against a net loss of Rs 97.90 crore in Q4 FY23. Total income increased by 5.15% YoY to Rs 1746.40 crore during the period under review.

The scrip rose 0.45% to end at Rs 750.75 on Friday, 14 June 2024.

Previous News
  Jubilant Pharmova announces board meeting date
 ( Corporate News - 11-Jul-24   10:16 )
  Jubilant Pharmova completes prepayment of term loan of USD 75 mn
 ( Corporate News - 25-Jun-24   15:21 )
  Indices trade with major gains; financial services edge higher
 ( Market Commentary - Mid-Session 25-Jun-24   14:32 )
  Jubilant Pharmova arm prepays term loan of Rs 626 crore
 ( Hot Pursuit - 25-Jun-24   12:47 )
  Jubilant Pharmova's contract manufacturing unit in Montreal concludes USFDA audit
 ( Corporate News - 18-Jun-24   18:55 )
  Jubilant Pharmova slides after Canada facility gets 15 observations from USFDA
 ( Hot Pursuit - 18-Jun-24   15:39 )
  Jubilant Pharmova unit to prepay $75 mln term loan
 ( Hot Pursuit - 15-Jun-24   08:51 )
  Jubilant Pharmova announces voluntary prepayment of USD 75 million term loan
 ( Corporate News - 14-Jun-24   18:09 )
  Broader mkt outperforms; realty shares advance
 ( Market Commentary - Mid-Session 10-Jun-24   12:45 )
  Jubilant Pharmova declines after US FDA issues 3 observations to Washington-based facility
 ( Hot Pursuit - 10-Jun-24   11:56 )
  Jubilant HollisterStier LLC's contract manufacturing facility completes USFDA inspection
 ( Corporate News - 08-Jun-24   13:57 )
Other Stories
  Lupin receives EIR from USFDA for Dabhasa facility
  13-Jul-24   16:48
  RVNL secures LoA worth Rs 132 cr from Central Railway
  13-Jul-24   16:38
  EMS bags order worth Rs 141-cr from Uttarakhand Power Corp.
  13-Jul-24   16:14
  Avenue Supermarts Q1 PAT climbs 17% YoY to Rs 774 cr in FY25
  13-Jul-24   16:00
  Sunteck Realty pre-sales climbs 30% YoY to Rs 502 cr in FY25
  13-Jul-24   15:32
  Fitch Ratings revises outlook on ratings of Tata Steel to 'negative'
  13-Jul-24   14:46
  5Paisa Capital Q1 PAT jumps 38% YoY in FY25
  13-Jul-24   14:39
  HCL Tech records PAT of Rs 4,257 crore in Q1; EBIT margin at 17.1%
  13-Jul-24   11:59
  IREDA Q1 PAT rises 30% YoY to Rs 384 cr in FY25
  13-Jul-24   09:00
  GTPL Hathway slides after Q1 PAT drops 60% YoY to Rs 14 cr in FY25
  12-Jul-24   15:40
Back Top